Nuvalent (NUVL)
NASDAQ:NUVL
NUVL Stock Chart & Stats
$102.45
-$0.36(-0.45%)
At close: 4:00 PM EST
$102.45
-$0.36(-0.45%)
Day’s Range― - ―
52-Week Range$55.54 - $113.02
Previous CloseN/A
Volume65.93K
Average Volume (3M)537.96K
Market Cap
$8.05B
Enterprise Value$7.24B
Total Cash (Recent Filing)$1.37B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 07, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding73,181,750
10 Day Avg. Volume554,345
30 Day Avg. Volume537,964
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)5.86
Price to Sales (P/S)0.00
P/FCF Ratio-26.57
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.41
Forecast
1Y Price Target
$140.93Price Target Upside37.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-5.56
Revenue Forecast (FY)$14.10M
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation - Intracranial ActivityAnalyst notes that zidesamtinib's superior brain penetration and higher intracranial complete response rate versus a competing ROS1 inhibitor provides a clear clinical advantage that may drive physician preference for patients with brain metastases.
Pipeline And Commercial PreparednessAnalyst points out that a wholly owned pipeline across ROS1, ALK, and HER2 programs combined with strong cash resources and active commercial hiring positions the company to pursue independent global launches and capture market share.
Regulatory PathwayAnalyst highlights that using shorter post-response follow-up for pretreated patients could support a faster regulatory filing and initial approval for zidesamtinib, potentially accelerating patient access and revenue realization.
Bears Say
Execution And Approval RiskAnalyst cautions that the positive outlook depends on successful clinical data and regulatory approvals for lead candidates, creating execution and approval risk that could negatively affect the stock if trials or filings encounter setbacks.
Target-specific Development RiskAnalyst warns that the forthcoming development candidate targets a less validated oncology target and carries higher target risk than the company's established programs, increasing the likelihood of development failure.
Nuvalent News
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $55.53 and its highest was $113.02 in the past 12 months.
What is Nuvalent’s market cap?
Nuvalent’s market cap is $8.05B.
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is May 07, 2026 which is in 35 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on Feb 26, 2026. The company reported -$1.58 earnings per share for the quarter, missing the consensus estimate of -$1.476 by -$0.104.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -1.34.
How many shares outstanding does Nuvalent have?
Nuvalent has 73,181,750 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$1.58 in its last earnings report, missing expectations of -$1.476. Following the earnings report the stock price went down -0.574%.
Which hedge fund is a major shareholder of Nuvalent?
Currently, no hedge funds are holding shares in NUVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvalent Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$140.93 (37.56% Upside)
$140.93 (37.56% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 205.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.40%
12-Months-Change
Fundamentals
Return on Equity
-42.07%
Trailing 12-Months
Asset Growth
23.73%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Stock 12 Month Forecast
Average Price Target
$140.93
▲(37.56% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---